Europeans live up to 30 years longer than they did a century ago, thanks in part to biopharmaceutical innovation. The development of drugs, targeted therapies, antibiotics and vaccines has helped prevent and manage diseases more effectively, underlining the critical role of biopharmaceuticals in shaping a healthier future.
In Romania, Antibiotice Iași has been a pioneer in these developments since 1955. It was the first manufacturer of penicillin for Romania and Southeastern Europe. Today, it is one of the largest producers of generic medicines in the European Union.
Antibiotice has 200 products, more than 1 350 employees and an important global presence. It has big goals to meet the increasing demand for medicines and therapies that will improve healthcare around the globe.
The support of EIB Advisory has helped our plans to expand production, improve the way we develop medicines and explore partnership opportunities in Romania and beyond.
Ioan Nani
Chief Executive of Antibiotice
The European Investment Bank signed a €25 million loan with Antibiotice to build a cutting-edge production site, with advanced machinery, packaging, and storage facilities. This investment, backed by the InvestEU Fund, will bolster Antibiotice’s research and development facilities, as well as its digitalisation efforts.
With funding from the InvestEU Advisory Hub, EIB Advisory experts, supported by specialised consultants, helped Antibiotice devise expansion strategies, reposition its portfolio, investigate new product formulations and build a new research and development centre to create new, high-value products.
The EIB Advisory support also enabled Antibiotice to find more financing from the Strategic Technologies for Europe Platform, providing further assistance for research and development, as well as manufacturing initiatives.
“The workshops we organised with Antibiotice opened up a dialogue and exchange of ideas to foster the company’s growth,” says Teodora Tataru, the Bank advisor behind this project.
Antibiotice’s expansion will create over 100 jobs and strengthen partnerships with universities and research institutes, helping to develop a highly skilled workforce.
Thanks to the loan from EIB, the company plans to double its sales and boost exports by at least 50%. This growth will be fuelled by digitalisation and streamlined operations, helping Antibiotice better serve European and global markets.
